Candice Roufosse

Candice Roufosse

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Candice Roufosse

Department of Immunology and Inflammation, Imperial College London, London, UK

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2017 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
MHMark Haas
Mark Haas
ALA. Loupy
A. Loupy
CLC. Lefaucheur
C. Lefaucheur
CRC. Roufosse
C. Roufosse
DGD. Glotz
D. Glotz
MMM. Mengel
M. Mengel
The kidney sessions of the 2017 Banff Conference focused on 2 areas: clinical implications of inflammation in areas of interstitial fibrosis and tubular atrophy (i-IFTA) and its relationship to T cell–mediated rejection (TCMR), and the continued evolution of molecular diagnostics, particularly in the diagnosis of antibody-mediated rejection (ABMR). In confirmation of previous studies, it was independently demonstrated by 2 groups that i-IFTA is associated with reduced graft survival. Furthermore, these groups presented that i-IFTA, particularly when involving >25% of sclerotic cortex in association with tubulitis, is often a sequela of acute TCMR in association with underimmunosuppression. The classification was thus revised to include moderate i-IFTA plus moderate or severe tubulitis as diagnostic of chronic active TCMR. Other studies demonstrated that certain molecular classifiers improve diagnosis of ABMR beyond what is possible with histology, C4d, and detection of donor-specific antibodies (DSAs) and that both C4d and validated molecular assays can serve as potential alternatives and/or complements to DSAs in the diagnosis of ABMR. The Banff ABMR criteria are thus updated to include these alternatives. Finally, the present report paves the way for the Banff scheme to be part of an integrative approach for defining surrogate endpoints in next-generation clinical trials.

28 May 2020 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
ALAlexandre Loupy
Alexandre Loupy
MHMark Haas
Mark Haas
CRCandice Roufosse
Candice Roufosse
MNMaarten Naesens
Maarten Naesens
BABenjamin Alexander Adam
Benjamin Alexander Adam
MMMichael H Mengel
Michael H Mengel
The XV. Banff conference for allograft pathology was held in conjunction with the annual meeting of the American Society for Histocompatibility and Immunogenetics in Pittsburgh, PA (USA) and focused on refining recent updates to the classification, advances from the Banff working groups, and standardization of molecular diagnostics. This report on kidney transplant pathology details clarifications and refinements to the criteria for chronic active (CA) T cell–mediated rejection (TCMR), borderline, and antibody‐mediated rejection (ABMR). The main focus of kidney sessions was on how to address biopsies meeting criteria for CA TCMR plus borderline or acute TCMR. Recent studies on the clinical impact of borderline infiltrates were also presented to clarify whether the threshold for interstitial inflammation in diagnosis of borderline should be i0 or i1. Sessions on ABMR focused on biopsies showing microvascular inflammation in the absence of C4d staining or detectable donor‐specific antibodies; the potential value of molecular diagnostics in such cases and recommendations for use of the latter in the setting of solid organ transplantation are presented in the accompanying meeting report. Finally, several speakers discussed the capabilities of artificial intelligence and the potential for use of machine learning algorithms in diagnosis and personalized therapeutics in solid organ transplantation.

1 November 2018 in Transplantation
Verified
Journal Article
Open access
CRCandice Roufosse
Candice Roufosse
NSNaomi Simmonds
Naomi Simmonds
MGMarian Clahsen-Van Groningen
Marian Clahsen-Van Groningen
MHMark Haas
Mark Haas
KHKammi J. Henriksen
Kammi J. Henriksen
JBJan U. Becker
Jan U. Becker
The Banff Classification of Allograft Pathology is an international consensus classification for the reporting of biopsies from solid organ transplants. Since its initial conception in 1991 for renal transplants, it has undergone review every 2 years, with attendant updated publications. The rapid expansion of knowledge in the field has led to numerous revisions of the classification. The resultant dispersal of relevant content makes it difficult for novices and experienced pathologists to faithfully apply the classification in routine diagnostic work and in clinical trials. This review shall provide a complete and simple illustrated reference guide of the Banff Classification of Kidney Allograft Pathology based on all publications including the 2017 update. It is intended as a concise desktop reference for pathologists and clinicians, providing definitions, Banff Lesion Scores and Banff Diagnostic Categories. An online website reference guide hosted by the Banff Foundation for Allograft Pathology (www.banfffoundation.org) is being developed, which will be updated with future refinement of the Banff Classification from 2019 onward.

1 January 2017 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
ALA. Loupy
A. Loupy
MHM. Haas
M. Haas
KSK. Solez
K. Solez
LRL. Racusen
L. Racusen
DGD. Glotz
D. Glotz
MMM. Mengel
M. Mengel
The XIII. Banff meeting, held in conjunction the Canadian Society of Transplantation in Vancouver, Canada, reviewed the clinical impact of updates of C4d-negative antibody-mediated rejection (ABMR) from the 2013 meeting, reports from active Banff Working Groups, the relationships of donor specific antibody tests (anti-HLA and non-HLA) with transplant histopathology, and questions of molecular transplant diagnostics. The use of transcriptome gene sets, their resultant diagnostic classifiers, or common key genes to supplement the diagnosis and classification of rejection, requires further consensus agreement and validation in biopsies. Newly introduced concepts include the i-IFTA score - comprising inflammation within areas of fibrosis and atrophy, and acceptance of transplant arteriolopathy within the descriptions of chronic-active T cell-mediated rejection (TCMR) or chronic ABMR. The pattern of mixed TCMR and ABMR was increasingly recognized. This report also includes improved definitions for TCMR and ABMR in pancreas transplants with specification of vascular lesions as well as prospects for defining a vascularized composite allograft rejection classification. The goal of the Banff process is ongoing integration of advances in histological, serological, and molecular diagnostic techniques to produce a consensus-based reporting system that offers: precise composite scores, accurate routine diagnostics, and applicability to next generation clinical trials.

27 October 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
MNMaarten Naesens
Maarten Naesens
CRCandice Roufosse
Candice Roufosse
MHMark Haas
Mark Haas
CLCarmen Lefaucheur
Carmen Lefaucheur
RMRoslyn B. Mannon
Roslyn B. Mannon
MMMichael H Mengel
Michael H Mengel
The XVI-th Banff Meeting for Allograft Pathology was held in Banff, Alberta, Canada, from 19th-23rd September 2022, as a joint meeting with the Canadian Society of Transplantation. To mark the 30th anniversary of the first Banff Classification, pre-meeting discussions were held on the past, present, and future of the Banff Classification. This report is a summary of the meeting highlights that were most important in terms of their effect on the Classification, including discussions around microvascular inflammation and biopsy-based transcript analysis for diagnosis. In a post-meeting survey, agreement was reached on the delineation of the following phenotypes: (1) "Probable antibody-mediated rejection (AMR)", which represents DSA-positive cases with some histological features of AMR but below current thresholds for a definitive AMR diagnosis; and (2) "Microvascular inflammation (MVI), DSA-negative and C4d-negative", a phenotype of unclear cause requiring further study, which represents cases with MVI not explained by DSA. Although biopsy-based transcript diagnostics are considered promising and remain an integral part of the Banff Classification (limited to diagnosis of AMR), further work needs to be done to agree on the exact classifiers, thresholds, and clinical context of use.

27 July 2012 in Transplantation
Verified
Journal Article
Closed access
MWMichelle Willicombe
Michelle Willicombe
PBPaul Brookes
Paul Brookes
RSRuhena Sergeant
Ruhena Sergeant
ESEva Santos-Nunez
Eva Santos-Nunez
CSCorinna Steggar
Corinna Steggar
DTDavid Taube
David Taube
The importance of human leukocyte antigen (HLA) matching in renal transplantation is well recognized, with HLA-DR compatibility having the greatest influence. De novo DQ donor-specific antibodies (DSAbs) are the predominant HLA class II DSAb after transplantation. The aim of this study was to establish the incidence and outcomes after the development of DQ DSAbs along with the impact of class II HLA mismatch on their development. We retrospectively analyzed 505 patients who received a renal-alone transplant between 2005 and 2010. We excluded patients who received an ABO- and HLA-incompatible allograft, which we defined as those with a positive crossmatch or preformed DSAbs detected by single-antigen beads only. Of 505 patients, 92 (18.2%) developed DSAbs, with 50 (54.3%) of these 92 patients having DQ DSAbs. Patients who developed DQ DSAbs were at significant risk for antibody-mediated rejection, transplant glomerulopathy, and allograft loss (P<0.0001). Of 505 patients, 108 (21.4%) were matched at both the DR and DQ loci, 284 (56.2%) were mismatched at both loci, 38 (7.5%) were matched at DR alone, and 75 (14.9%) were matched at DQ alone. Patients mismatched at both DR and DQ were at risk for developing class II DSAbs when compared with those mismatched at either DR or DQ alone, P=0.001, and were at risk for antibody-mediated rejection, P=0.001. DQ DSAbs are associated with inferior allograft outcomes. This study shows the importance of establishing the DQ match before transplantation to define immunologic risk.